CANCER CENTER FACILITIES The Kimmel Cancer Center is located on the campus of Thomas Jefferson University (TJU) and is part of Jefferson Medical College, founded in 1824. Jefferson Medical College is one of the largest private medical schools in the nation and is located in Center City Philadelphia (Fig. 3). The facilities strategic plan of TJU and TJUH has been developed. The KCC and its facilities are a centerpiece of the campus. The Biostatistical and Administrative offices of the Radiation Therapy Oncology Group (RTOG) are located a few blocks from KCC. as are the headquarters of the Coalition of Cancer Cooperative Groups (CCCG). The RTOG Translational Research Program Committee is co-chaired by Dr. Dicker, leader of the KCC's RRTB program. Dr. Comis, a new KCC Member, who is a faculty member of Drexel University, is the President and CEO of the CCCG and Group Chair of the Eastern Cooperative Oncology Group (ECOG). (Drexel University has a medical school and hospital campus in addition to strengths in biomedical engineering). Philadelphia has four medical schools and four NCI-designated Cancer Centers (University of Pennsylvania, Wistar Institute, Fox Chase Cancer Center and Kimmel Cancer Center). The Cancer Centers at Penn and Wistar are, approximately 20 blocks away from the KCC on the west side of the Schuylkill River. Because of this small distance, Penn and Wistar investigators often attend KCC seminars and functions and vice versa.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-15
Application #
8753680
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603
Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:
Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552

Showing the most recent 10 out of 807 publications